Showing 1961-1970 of 2314 results for "".
- Ophthalmos Institute Reports Positive Efficacy Data of Eyetas' Omega 3 Fatty Acids Supplementation on Dry AMD and Stargardt Diseasehttps://modernod.com/news/ophthalmos-institute-reports-positive-efficacy-data-of-eyetas-omega-3-fatty-acids-supplementation-on-dry-amd-and-stargardt-disease/2480325/Ophthalmos Research and Educational Institute (OREI) announced positive clinical and statistically significant topline results from a small randomized, double-blind multicenter study in Europe assessing the potential effects of omega 3 fatty acids supplementation (Eyetas) in modera
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op
- Aerie Announces Positive Phase 2b Study Results for Dry Eye Product Candidatehttps://modernod.com/news/aerie-announces-positive-phase-2b-study-results-for-dry-eye-product-candidate/2480279/Aerie Pharmaceuticals reported positive topline results of its phase 2b clinical study, COMET-1, for AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The randomized, double-masked, vehicle-controlled phase 2b clinical study
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun
- OD-OS Introduces Teleguidance Software for Navilas 577s Navigated Retina Laserhttps://modernod.com/news/od-os-introduces-teleguidance-software-for-navilas-577s-navigated-retina-laser/2479491/OD-OS has launched additional remote access capabilities for its Navilas Laser System 577s to address common challenges in ophthalmology that were enhanced during the COVID-19 pandemic. The new teleguidance capabilities give doctors remote access to the device to pre-plan a retinal laser treatmen
- Is Undergraduate Ophthalmology Teaching in the United Kingdom Still Fit for Purpose?https://modernod.com/news/is-undergraduate-ophthalmology-teaching-in-the-united-kingdom-still-fit-for-purpose/2479479/An editorial in the publication Eye examines the reasons behind why an increasing number of junior doctors and general practitioners in the UK are losing confidence in their ophthalmic knowledge. Such factors cited in the d
- American Academy of Optometry Foundation Announces Award Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/Jonathan D. Lam, MD, OD, was this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Lam is a primary care/ocular disease resident at the Chinle Comprehensive Health Care Facility in Chinle, Arizona. Douglas W. Hopkins, OD, FAAO, was a leader within the Primary Care Section
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- Santen and Sydnexis Execute an Exclusive Licensing Agreement for SYD-101, an Investigational Treatment for Progressive Childhood Myopiahttps://modernod.com/news/santen-and-sydnexis-execute-an-exclusive-licensing-agreement-for-syd-101-a-novel-investigational-treatment-for-progressive-childhood-myopia/2479443/Santen and Sydnexis have signed an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation for childhood myopia, for Europe, the Middle East, and Africa (EMEA). SYD-101 is currently undergoing a large multicenter phase 3 clinical trial, the S